Ergotamine — Membership Pricing

Other medications in Pain & Inflammation

• Etodolac
• Fenoprofen
• Flurbiprofen
• Frovatriptan
• Hydrocodone
• Hydrocodone-Acetaminophen
• Hydromorphone
• Ibuprofen

About Ergotamine

Ergotamine is a powerful medication prescribed to treat acute migraine and cluster headaches. It works by narrowing blood vessels around the brain to reduce migraine symptoms. Unfortunately, many patients face high out-of-pocket costs. TheDrugClub members enjoy significant savings on ergotamine, including $0 co-pays and convenient free home delivery to your door.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ergotamine is approved for (FDA label)

Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia".

Source: Read the full FDA label on DailyMed. Label effective date: February 25, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ergotamine (FDA label)

WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of ergotamine tartrate, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See also CONTRAINDICATIONS and WARNINGS section)

Source: FDA prescribing information (DailyMed). Set ID: a9582fdb-7ddd-4f69-aa7a-66247cdb8c92. SPL document ID: 2ef9fa55-cdc3-dc0a-e063-6394a90a0e5f. Label effective date: February 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ergotamine (FDA label)

Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times. These include ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes and muscle pains. Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses. Other cardiovascular adverse effects include transient tachycardia or bradycardia and hypertension. Gastrointestinal: Nausea and vomiting. Neurological: paresthesias, numbness, weakness, and vertigo. Allergic: Localized edema and itching. Fibrotic Complications: ( See WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: a9582fdb-7ddd-4f69-aa7a-66247cdb8c92. SPL document ID: 2ef9fa55-cdc3-dc0a-e063-6394a90a0e5f. Label effective date: February 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ergotamine (FDA label)

Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities ( See PRECAUTIONS: Drug Interactions ), with some cases resulting in amputation. There have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. Because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of CYP 3A4 (e.g., ketoconazole, itraconazole) (See WARNINGS: CYP 3A4 Inhibitors ). Ergomar ® Sublingual Tablets may cause fetal harm when administered to pregnant women. Ergomar ® Sublingual Tablets are contraindicated in women who are or may become pregnant.

Source: FDA prescribing information (DailyMed). Set ID: a9582fdb-7ddd-4f69-aa7a-66247cdb8c92. SPL document ID: 2ef9fa55-cdc3-dc0a-e063-6394a90a0e5f. Label effective date: February 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ergotamine (FDA label)

CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease inhibitors) See CONTRAINDICATIONS and WARNINGS . Ergomar ® Sublingual Tablets (Ergotamine Tartrate Sublingual Tablets USP) should not be administered with other vasoconstrictors. Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics.

Source: FDA prescribing information (DailyMed). Set ID: a9582fdb-7ddd-4f69-aa7a-66247cdb8c92. SPL document ID: 2ef9fa55-cdc3-dc0a-e063-6394a90a0e5f. Label effective date: February 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.